You are here: Industry Insights > Aridis

News List

Aridis Reports Positive Preclinical Efficacy Data for Inhaled Treatment for COVID-19 americanpharmaceuticalreview
October 23, 2020
Aridis Pharmaceuticals announced the development of a highly neutralizing monoclonal antibody AR-711, discovered from convalescent COVID-19 patients that successfully eliminated all detectable SARS-CoV-2 virus in infected animals at ...
Aridis Receives Orphan Drug Designation from the EMA for AR-501 americanpharmaceuticalreview
July 22, 2019
ridis Pharmaceuticals announced the European Medicines Agency (EMA) has granted Orphan Drug Designation to AR-501, the Company's inhaled formulation of gallium citrate for treatment of lung infection in patients with cystic fibrosis.
AR-501 Enrolls First Subject in Trial for Treatment of CF Chronic Lung Infections americanpharmaceuticalreview
December 13, 2018
Aridis Pharmaceuticals announced the first subject has been enrolled in a Phase 1/2a clinical study evaluating the investigational candidate AR-501 for treatment of chronic bacterial lung infections in patients with cystic fibrosis (CF).....